New drug VBC103 targets tough cancers in early trial

NCT ID NCT07299747

Recruiting now Disease control Sponsor: VelaVigo Bio Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called VBC103 in people with advanced solid tumors that have not responded to standard treatments. VBC103 is designed to target two proteins on cancer cells to deliver a toxic payload. The trial will enroll 255 participants to find the safest dose and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VBC103 (a bispecific antibody-drug conjugate targeting Nectin-4 and TROP2)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase trial (Phase I/IIa) focused on safety and dosing, so it is uncertain whether VBC103 will effectively shrink tumors or improve survival. Side effects may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARTICIPANTS WITH ADVANCED SOLID TUMOR MALIGNANCIES

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 201209, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.